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Abstract
MicroRNAs (miRNA) have emerged as key regulators of cell lineage differentiation and cancer. We used precursor miRNA
profiling by a novel real-time QPCR method (i) to define progressive stages of endothelial cell transformation cumulating in
Kaposi sarcoma (KS) and (ii) to identify specific miRNAs that serve as biomarkers for tumor progression. We were able to
compare primary patient biopsies to well-established culture and mouse tumor models. Loss of mir-221 and gain of mir-15
expression demarked the transition from merely immortalized to fully tumorigenic endothelial cells. Mir-140 and Kaposi
sarcoma–associated herpesvirus viral miRNAs increased linearly with the degree of transformation. Mir-24 emerged as a
biomarker specific for KS.
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Introduction
Kaposi sarcoma (KS) is one of the few human cancers of
endothelial origin. KS remains the most frequent AIDS-associated
malignancy even in populations with ready access to highly active
anti-retroviral therapy (HAART) [1,2]. Today, approximately one
third of AIDS-KS tumors develop in patients on successful long-
term HAART, i.e. with near normal T lymphocyte counts and
undetectable HIV viral loads [3]. In sub-Saharan Africa, KS ranks
among the most common cancers overall since HIV turned the
endemic form of this disease into an epidemic. By comparison to
epithelial cancers, endothelial-lineage cancers are less common
still, and most study endothelial cells because of their ancillary role
in tumor angiogenesis rather than their role as the driving force of
tumor formation. In KS, endothelial lineage cells drive tumor
growth. Recent data suggest that tumor-associated stromal cells,
including endothelial cells can acquire epigenetic or perhaps even
genetic features of transformation, which in turn support tumor
growth [4,5,6]. KS offers the opportunity to study endothelial cell
transformation and tumorigenesis in detail, and miRNAs provide
one possible means of large-scale, stable epigenetic reprogram-
ming. To test the hypothesis that miRNA signatures delineate
progressive stages of endothelial cell transformation resulting in
metastatic KS, we used high throughput, quantitative real-time
PCR-based pre-miRNA profiling.
KS is tightly associated with Kaposi sarcoma associated
herpesvirus (KSHV) [7,8,9]. Every tumor cell carries the virus
and expresses at least the viral latent proteins [10,11]. Here, we
show for the first time using primary patient biopsies that every KS
tumor transcribes the viral miRNAs (miRNA) as well.
KSHV is also the etiological agent of the B cell lineage tumor
primary effusion lymphoma (PEL), as well as the B cell lineage
hyperplasia, plasmablastic variant of multicentric Castleman
disease (MCD) [12,13]. This dichotomous phenotype (lymphoid/
endothelial) allows testing of the hypotheses that the miRNA
profile for these two cancers reflect (a) their tissue of origin, (b)
progressive cancer signatures, (c) a signature induced by latent
viral infection or (d) a combination of all.
The miRNAs have emerged as master regulators of cell lineage
differentiation and key modulators of cancer (reviewed in [14]).
They are small, 22 nucleotide non-coding RNA molecules that,
upon incorporation into the cytoplasmic RNA-induced silencing
complex (RISC), can inhibit translation of target messenger RNAs
and ultimately target them for degradation. At present, the Sanger
database has recorded 678 human miRNAs [15] each capable of
targeting up to several hundred different mRNAs. KSHV encodes
multiple viral miRNAs [16,17,18,19], including a viral ortholog to
miR-155 [20,21]. Even though some targets for these viral
miRNAs have been identified [22], exactly how they function in
KS tumorigenesis is unresolved.
MiRNA profiling has provided invaluable insights into tissue
development and cancer. Many tumor-specific and cell lineage-
specific signatures have been compiled (e.g. [23,24,25] and many
others). We previously established the miRNA signature for PEL
[26] using real-time quantitative PCR. Pre-miRNA profiling has
also been used successfully to stratify human tumors. It often
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found that pre-miRNA profiling provides non-redundant infor-
mation with utility for tumor classification. Pre-miRNAs are an
intermediate product for mature miRNAs, analogous—in the
widest sense—to mRNAs being an intermediate product for
proteins. They are generated by Drosher and DGCR8 from the
nascent pri-miRNAs and eventually exported by Exportin-5 to the
cytoplasm. For the purpose of profiling they offer advantages
because they are longer (,70 nt), each nucleotide contributing
additional specificity in diagnostic assay, as opposed to mature
miRNAs, which because of their limited target region of only ,22
nt impose limitations due to cross hybridization and variable
primer/probe annealing efficiency for different miRNAs. Here, we
use real-time QPCR-based profiling to discern pre-miRNAs that
identify KS, KSHV infection and distinct, progressive stages of
endothelial cell transformation.
KSHV transforms primary human endothelial cells in culture
[30], though this is a rare event. KSHV infection consistently only
leads to morphological alterations (‘‘spindling’’) and reduced
growth factor dependence [31,32,33,34]. KSHV infection of
immortalized human endothelial cells leads to extended survival,
and growth factor independence [35,36,37] but not complete
transformation, as defined by the ability to form tumors in nude
mice. Importantly, during latent viral infection, lymphatic
endothelial cell differentiation markers remain expressed, and if
not already of lymphatic endothelial origin, KSHV is capable of
inducing this phenotype in human endothelial cell preparations
derived from other tissues such as the vasculature [35,38,39].
KSHV infection per se does not induce dedifferentiation of
lineage-committed lymphatic endothelial cells. A study by An et al.
succeeded in deriving two fully tumorigenic clones of lymphatic
endothelial cells (TIVE E1 and TIVE L1) that maintain KSHV in
the absence of selection [40]. Introduction of KSHV into murine
endothelial progenitor cell preparations also resulted in the clonal
outgrowth of at least one fully transformed cell line [41]. By
contrast, attempts to culture tumor cells directly from KS lesions
largely failed. Today, we have only a single KS tumor derived cell
line, SLK, which is fully transformed, but has lost the KSHV
genome [42]. Together with primary KS biopsies, these culture
systems exemplify multiple stages of endothelial cell cancer
progression (Table 1). In this study, we used high throughput
profiling to identify cell lineage and cancer progression stage-
specific pre-miRNAs for this representative set of KSHV-infected
and uninfected immortalized endothelial cells, KS biopsies and
PEL lymphoma cell lines.
Results
Experimental Approach
A total of 47 samples were selected for profiling at the DNA and
pre-miRNA level (Table 1 and Table S1). These include the
largest number of PEL cell lines to date (n=14). Four KSHV-
Table 1. Samples representative of different stages in
endothelial cell transformation
SAMPLES KSHV TUMOR
a REFERENCE STAGE
e
Cell lines:
tertHUVEC - -
b E
tertHMVEC - -
b E
tertHUVEC-2 + -
b EK
tertHUVEC-6 + -
b EK
tertHMVEC-1 + -
b EK
E1 TIVE ++
c ET
L1 TIVE ++
c ET
SLK - +
d ET
E1 Tumor-1 ++ +
c ETM
E1 Tumor-2 ++ +
c ETM
E1 Tumor-3 ++ +
c ETM
E1 Tumor-4 ++ +
c ETM
E1 Tumor-5 ++ +
c ETM
Biopsies:
KS-1 + +++ this study KS
KS-2 + +++ this study KS
KS-3 + +++ this study KS
KS-4 + +++ this study KS
KS-5 + +++ this study KS
KS-6 + +++ this study KS
KS-7 + +++ this study KS
KS-8 (2007) + +++ this study KS
KS-8 (2008) + +++ this study KS
a.Relative tumorigenicity: + tumor-forming capability in xenograft models; ++
tumor in matrigel support in mice at 56105 cell; +++ KS tumor in a person.
b.Wang L, Damania B (2008) Kaposi sarcoma-associated herpesvirus confers a
survival advantage to endothelial cells. Cancer Res 68: 4640–4648.
c.An, F.Q., et al., Long-term-infected telomerase-immortalized endothelial cells: a
model for Kaposi sarcoma-associated herpesvirus latency in vitro and in vivo. J
Virol. 2006. 80(10): p. 4833–46.
d.Herndier BG, et al. (1994) Characterization of a human Kaposi sarcoma cell line
that induces angiogenic tumors in animals. AIDS 8: 575–581.
e.Stage identifies biological distinct classes of transformation: uninfected
endothelial cells (E), KSHV-infected endothelial cells (EK), endothelial cells that
have the ability to form tumors in nude mice (ET, which includes the KSHV-
positive TIVE- E1, L1 cell lines as well as KSHV-negative SLK cells), xenograft
tumors of TIVE- E1 cells consisting of 5 independent samples (ETM), KS patient
biopsies (KS).
doi:10.1371/journal.ppat.1000389.t001
Author Summary
MicroRNAs are key regulators of cancer and development.
We can use their pattern of expression to classify different
cancers or in our case different stages in cancer develop-
ment. We used a novel method to define progressive
stages for Kaposi sarcoma (KS), which is a cancer of the
endothelial cells. We identified specific precursor-miRNAs
that accurately identify stages of KS tumor progression. For
the first time, we were able to profile KS patient material.
This is difficult to come by, but it is more closely related to
the human cancer than even the best cell culture models.
Our work statistically defined clusters of pre-miRNAs, each
signifying one step in cancer progression. This is the first
time that precursor miRNAs profiling was used to define
cancer stages. It is also the first time that we have defined
makers of any kind that allow us to distinguish between
different types of the endothelial cancer KS. Loss of mir-221
precursor miRNA and gain of mir-15 precursor miRNA
expression demarked the transition from merely immortal
to fully tumorigenic cells. Mir-140 and Kaposi sarcoma–
associated herpesvirus viral microRNAs increased progres-
sively with the degree of transformation, i.e. more
aggressive stages expressed higher levels of these bio-
markers. High levels of the precursor microRNA mir-24
emerged as a biomarker only in patient derived KS samples,
not in any of the culture models.
KS Pre-MicroRNA Profile
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they are expected to transcribe miRNAs that are common to B
lineage lymphomas. The pre-miRNA difference between these
samples and PEL defines part of the PEL signature [26]. For this
study, we added 9 tonsil tissues as a normal tissue control. These
serve to determine which pre-miRNAs are highly abundant in B
cells, as tonsils consist of over 50% B cells, including germinal
center (GC) B cells, which many assume to be the normal
precursor of PEL [43,44,45]. Two T-cell lymphoma cell lines were
included to differentiate T cell pre-miRNAs.
For the first time, KS primary biopsies were also assessed for
pre-miRNA transcription. We collected 9 AIDS-KS skin biopsies
from the Americas. The biopsies were collected by individuals with
experience in KS clinical trials. They are considered representative
lesions for the purpose of tumor and response staging. The
majority of cells in each biopsy are KSHV-infected endothelial
cells [11,46,47]. All biopsies were from male subjects with a
median age of 44 years (range 30–57). Patients had biopsy-
confirmed KS and were on HAART as well as concurrent
chemotherapy. Their median CD4 count was 78 cells/microliter
(range 7–402). CD4 counts were not available for one subject. All
patients had extensive cutaneous KS and with the exception of one
are alive at present. Tumor samples were obtained within the last
three years. Hence, these patients represent the current post-
HAART AIDS epidemic.
Two immortalized virus-negative endothelial cell lines were
included in the arrays, as well as isogenic controls carrying latent
KSHV [36]. A similar model exists in the E1 TIVE and L1 TIVE
cell lines [40]. These currently represent the best human cell
culture tumor model for KS, as these two cell lines induce KS-like
tumors in nude mice with 100% efficiency. Also included is the
only known KS-derived cell line, SLK [42], which has lost the
KSHV genome, but is tumorigenic in mice.
As positive control we used DNA as the input and real-time
QPCR and primers directed against the pre-miRNA as described
[26]. We were able to independently verify KSHV-infection status
for each sample. Likewise, the EBV miRNA genes were detectable
only in the EBV-positive PEL and BL cell lines, but not KS or any
other samples. EBV miRNA genes were not detectable in normal
tonsil tissue. The relative copy number for the KSHV miRNA
genes was significantly lower in KSHV carrying endothelial cell
lines compared to PEL (see Figure S4). This is consistent with
earlier reports that PEL carry more viral plasmids (50,100
copies/cell) than KS (,10 copies/cell) and KSHV-infected
endothelial cell cultures [46,48,49,50]. Among the KSHV infected
endothelial cell models, the HMVEC carried the highest KSHV
genome number, suggesting that they are most capable of
maintaining high levels of the KSHV plasmid. This is consistent
with earlier studies showing that not all endothelial cells are
equally permissive for KSHV infection, which drives reprogram-
ming towards lymphatic endothelial cells [35,38,39].
Unsupervised clustering reveals the pre-miRNA profile of
KS
Our pre-miRNA data set, which included 160 primer pairs,
representing 145 cellular miRNAs, 9 viral miRNAs, 2 viral
mRNAs and 4 cellular RNAs (U6), and 47 samples consisted of
.20,000 individual data points. QPCR measures target abun-
dance on a 2log scale with higher CT numbers reflecting lower
abundance. For this analysis, the average of the triplicate CT
values was taken. These were normalized to U6 levels, to give
dCT. Note that dCT values represent the underlying pre-miRNA
levels on a 2log scale thus facilitating robust clustering [51,52].
Following normalization, each sample set was Z-standardized to
remove variation between samples [53,54].
Figure 1 shows the heatmap representation after hierarchical
clustering for the full panel of samples, with red indicating a
higher level of expression and blue indicating a lower level of
expression compared to the median of all data (white). 6 distinct
groups were identified. These represent the minimal number of
non-overlapping clusters based on principal component analysis
(PCA) (data not shown). The first two groups represent the pre-
miRNAs that are unchanged across all samples, those with low
levels of expression (I in blue) and those with high levels of
expression across all samples (II in red). The KSHV pre-miRNAs
all cluster in group III. Group IV represents the pre-miRNAs that
are downregulated in KSHV-positive cells. 20 miRNAs are
contained in this group. Group V represents 11 cellular miRNAs
that are highly expressed in immortalized HUVEC and HMVEC
cells, both uninfected and KSHV-infected, but not any of the
tumor cell lines and biopsies. They do not appear to be
significantly enriched in any of the other endothelial cell types
(KS or TIVE). Finally, group VI contains cellular miRNAs that
are downregulated in all B-cell lymphomas, including PEL, vis-a `-
vis tonsil and KS.
To remove the impact of lineage-specific determinants [B cell
(PEL and Tonsil) vs. endothelial cell] from the analysis, we
analyzed the two KSHV-associated cell types separately. Our
analysis of PEL specific miRNAs was previously published [26]
and analysis of the extended data set confirmed this observation
(data not shown). When the endothelial-derived subset of samples
was analyzed alone, a clearer picture emerged that highlights
similarities and disparities between different stages of endothelial
cell transformation (Figure 2A). The groups represent the minimal
number of non-overlapping clusters based on PCA (data not
shown). The first two groups (I and II) represent miRNAs with
minimal discernable patterns across all samples—at least at the
power of our analysis. Blue indicates low levels while red indicates
comparable high levels of miRNAs, vis-a `-vis the median of all data
in this set. This is not to say that pre-miRNAs within these two
clusters did not exhibit any change between samples classes, only
that these changes were smaller compared to others and therefore
less interesting from a biomarker perspective. For example, mir-
222 clusters in group II because it was more highly transcribed in
all samples relative to 50% of all other pre-miRNAs. Nevertheless
mir-222 was downregulated in KSHV-infected, tumorigenic
samples, compared to EC. The pattern of mir-222 parallels that
of mir-221, which is expected because of their known co-
regulation [55,56]. However, the range of change was much
larger for mir-221 as seen in group IV.
Group III shows the pre-miRNAs that are upregulated upon
KSHV infection of EC and increased even more in KS and in the
tumorigenic L1/E1 clones. This group includes the KSHV pre-
miRNAs along with the cellular pre-miRNAs let-7a-1, let-7a-2, let-
7a-3, mir-7-1, mir-27a, mir-125b-2, mir-140, mir-152, mir-181c,
mir-194-2, and mir-220. The detailed transcription pattern for this
group is shown as a bar graph for pre-miRNA let-7a-3 (Figures 2D,
all bar graphs show Z-standardized values of median dCTU6).
To demark the degree of viral latent transcription, LANA
mRNA levels are shown (Figure 2B). LANA is transcribed in all
KSHV-positive samples but not the KSHV-negative SLK,
HUVEC or HMVEC cell lines. KSHV latent RNA levels
correlated positively with increasing tumor-forming capability of
the infected cells (p#10
213 by ANOVA of linear model). They
were undetectable in uninfected cells, lowest in KSHV-infected
HUVEC and E1/L1 cells in culture, higher in E1 mouse tumors
and KS lesions and highest in PEL (data not shown). This was
KS Pre-MicroRNA Profile
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miRNA transcription levels correlated KSHV plasmid copy
number (DNA) as measured by real-time QPCR using the same
primer sets with DNA as input (data not shown). The positive
correlation between the level of viral miRNA and the relative
tumorigenicity of the sample class supports a causal role for
miRNA in KS tumorigenesis. It suggests that KSHV miRNAs are
required to maintain the KS tumor phenotype. Group IV contains
a set of 8 cellular miRNAs that are highest expressed in KS tumors
only, compared to cell lines. These include mir-24-2, mir-30c-2,
mir-125a, mir-130a, mir-196, mir-215, mir-218-2, and mir-367.
The bar graph of mir-24-2 levels in Figure 2E serves as an
example for the pre-miRNA expression pattern of this group, for
which miRNA levels were highest in KS tumors and significantly
lower in other samples whether KSHV-infected or not. As
expected for all primary tumor samples, we observed more
heterogeneity in the KS biopsies compared to clonal cell lines.
This necessitated the use of 9 independent biopsies, which is a
larger number then used in prior KS mRNA array analyses. With
this number of biopsies, PCA analysis validated the significance of
cluster membership for all pre-miRNA, including those that group
in cluster IV.
Figure 1. Pre-miRNA profiling of all samples. Shown is a heatmap, with blue indicating low levels of signal, white intermediate, and red high
levels of signal, when comparing across all primer pairs. The horizontal axis indicates samples: PEL indicates PEL, B indicates KSHV-negative B cell
lymphoma, T indicates T cell lymphoma, Tonsil indicates tonsil and Endothelial indicates all endothelial culture cell models, including SLK, E1 and L1
TIVE, and infected and uninfected HUVEC and HMVEC cells. Additionally, viral status is shown, with + indicating KSHV-positive and – indicating KSHV-
negative. The vertical axis indicates the pre-miRNA. Groups I and II represent the miRNAs that are unchanged across all samples. Group III indicates
cellular and KSHV miRNAs induced upon KSHV infection. Group IV represents the miRNAs that are downregulated in KSHV-positive infection. Group V
represents 11 cellular miRNAs highly expressed in the HUVEC and HMVEC cells, both uninfected and infected. Group VI contains cellular miRNAs that
are downregulated in all B-cell lymphomas, including PEL.
doi:10.1371/journal.ppat.1000389.g001
KS Pre-MicroRNA Profile
PLoS Pathogens | www.plospathogens.org 4 April 2009 | Volume 5 | Issue 4 | e1000389Figure 2. Pre-miRNA profiling of primary KS biopsies and endothelial derived cell cultures. (A) Shown is a heatmap, with blue indicating
low levels of signal, white intermediate, and red high levels of signal, when comparing across all primer pairs. The horizontal axis indicates samples:
KS indicates primary KS biopsies and Endothelial indicates all endothelial culture cell models, including SLK, E1 and L1 TIVE, and infected and
uninfected HUVEC and HMVEC cells. Additionally, viral status is shown, with + indicating KSHV-positive and – indicating KSHV-negative. The vertical
axis indicates the pre-miRNA. Group I and II represent the miRNAs that are unchanged in all samples. Group III shows the cellular and viral miRNAs
that are upregulated upon KSHV infection. Group IV indicates viral and cellular miRNAs upregulated specifically in KS, group V for E1 and L1 TIVE, and
group VI for uninfected and infected HUVEC and HMVEC cells. Group VII are cellular miRNAs downregulated in uninfected and infected HUVEC and
HMVEC cells. Bar graphs representative of each group described are shown on the left (B–H). All samples are shown in the same order as the
clustering, with KS representing primary KS biopsies and Endothelial indicating all endothelial cell culture models profiled. Again, viral status is also
listed. In the bar graphs, each cell type is divided by a black bar. All bar graphs are dCT U6 normalized and Z-standardized. (B) Lana expression is high
in all KSHV-positive cell lines and not present in KSHV-negative cell lines. (C) KSHV-mir-K2 is upregulated in all KSHV-positive samples, with the
highest level of expression in primary KS biopsies, intermediate in E1 and L1 TIVE cells and lowest in infected HUVEC and HMVEC cells. (D) Cellular
miRNA let-7a-3 shows a similar expression pattern of increased expression upon KSHV infection. (E) Mir-24-2 has increased expression in primary KS
biopsies, as compared to other cell types. (F) Mir-32 has increased expression in E1 and L1 TIVE cells, as compared to other cell types. (G) Mir-29a has
increased expression in both infected and uninfected HUVEC and HMVEC cells while mir-370 (H) shows reduced expression in this group, as
compared to other cell types.
doi:10.1371/journal.ppat.1000389.g002
KS Pre-MicroRNA Profile
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highest levels in the E1 and L1 TIVE cell lines. These pre-
miRNAs were present at higher levels in E1/L1 cells even
compared even to KS biopsies. These are mir-17, mir-22, mir-28,
mir-32, mir-128b, mir-135b, mir-143, mir-151, mir-181b-2, mir-
205, mir-213, mir-216 and mir-372. The bar graph of mir-32
expression in Figure 2F is an example of the pre-miRNA
expression pattern for this group.
Group VI consists of 13 pre-miRNAs with highest levels in the
non-tumorigenic endothelial HUVEC and HMVEC cell lines,
whether KSHV-infected or not. These are mir-26b, mir-29a, mir-
34b, mir-92-1, mir-93, mir-133a-1, mir-133a-2, mir-193, mir-221,
mir-223, mir-301, mir-323 and mir-346. 11 of these miRNAs were
also contained in the HUVEC/HMVEC upregulated cluster from
the larger data set (Figure 1). Additionally, mir-34b and mir-92-1
fell into this group upon clustering of only the endothelial cell data.
The histogram of mir-29a expression in Figure 2G is an example
of the pre-miRNA transcription pattern for this group, with
highest levels in both infected and uninfected HUVEC/HMVEC
cells and significantly lower levels in all other samples.
Group VII is the inverse of group VI and consists of miRNAs
with undetectable levels in the endothelial HUVEC and HMVEC,
whether KSHV-infected or not. This group compromises 11
cellular pre-miRNAs: mir-7-2, mir-9-2, mir-30b, mir-107, mir-
135a-2, mir-153-1, mir-153-2, mir-181b-2, mir-197, mir-325 and
mir-370. The bar graph of mir-370 expression in Figure 2H is an
example of the pre-miRNA transcription pattern of this group.
In sum, unsupervised clustering as a discovery tool identified (i)
distinct stages of endothelial cell transformation and (ii) specific
pre-miRNAs that serve as biomarkers for each of them.
One of the concerns in profiling cell lines in culture is that the
transcription signature may be reflective of a particular prolifer-
ation state rather than a general characteristic of the tumor
subtype. Proliferation dependence is well documented for mRNA
levels in fibroblasts [57]. For several miRNAs, too, proliferation
and miRNA transcription rates are linked [58,59,60,61,62,63,64].
To guard against this fallacy, we only used RNA derived from log-
phase cells for our profiling analysis. Nevertheless, to test the
hypothesis that some miRNA levels were proliferation state
dependent, we conducted a time course experiment for the E1
and L1 TIVE cell lines (see Figures S1 and S2). This revealed a
very limited number of pre-miRNAs that were enriched in log-
phase cells compared to stationary phase cells and vice versa. They
were at the lower limit of detection and additional experiments are
needed to validate the biological significance of this observation.
miRNAs as endothelial cell tumor stage biomarkers
Unsupervised comparisons represent the first level of large scale
profiling studies. Here, they revealed (i) the existence of multiple
distinct steps of endothelial cell transformation and (ii) pre-
miRNAs that were selectively transcribed in one or more stages
and that therefore serve as biomarkers. The latter were further
validated by supervised class prediction methods. Based upon pre-
miRNA clustering (Figure 1 and 2) and published phenotype
(Table 1), we defined the following classes: Endothelial cells (E),
KSHV-infected endothelial cells (EK), endothelial cells that have
the ability to form tumors in nude mice (ET), which includes the
KSHV-positive TIVE- E1, L1 cell lines as well as KSHV-negative
SLK cells), xenograft tumors of TIVE- E1 cells consisting of 5
independent samples (ETM), KS patient biopsies (KS), PEL (P),
and as negative controls tonsil (TN) and non-KSHV associated
lymphomas (TM).
First, we conducted pair-wise comparisons between classes using
the median dCTU6 for each class (Figure S2). The two TERT-
immortalized EC cell lines HUVEC and HMVEC exhibited a
nearly identical pre-miRNA transcription pattern (r
2=0.7238).
Infection with KSHV of these immortalized cell lines did result in
changes (r
2=0.6798). Of note, this comparison is between median
levels for the two EC cell lines (HUVEC and HMVEC) and three
independent clones of tightly latently infected TERT-HUVEC
cells. Thus, it exhibited more variability than a pair-wise
comparison of just two cell lines. The most drastic change in
overall pre-miRNA transcription emerged when comparing
KSHV-infected, non-tumorigenic EC cell lines to the two
KSHV-infected, highly tumorigenic E1/L1 cell lines. Here, we
failed to detect any linear correlation. The two TIVE cell lines E1
and L1, of course, exhibited a strikingly similar pattern of pre-
miRNA transcription as shown in detail in Figure S4 and Figure
S1. The pair-wise comparison between E1/L1 cells in culture to
E1 xenograft tumors showed a reasonable linear correlation, but
less than between different culture models (r
2=0.5684). Analysis of
residuals identified all KSHV pre-miRNAs as well as mir-223 to
be significantly upregulated in the tumorgraft (data not shown).
Since there are no human infiltrating lymphocytes in the SCID
mouse model, and since the tumor vasculature is made of murine
endothelial cells, any changes in pre-miRNA composition reflect
the grafted human tumor cells. Importantly, the comparison
between E1 xenograft tumor biopsies and patient KS biopsies
yielded a better correlation (r
2=0.5846) than between E1/L1 cells
in culture and E1 tumor grafts. This reinforces the results of the
phenotypic characterization of E1/L1 cells [40] and demonstrates
that the E1/L1 xenograft model adequately mimics primary KS
patient biopsies.
Next, we identified and validated a set of diagnostic pre-miRNA
biomarkers that signify the different steps of endothelial cell
transformation. To do so we used the miRNAs identified by
hierarchical clustering (Figure 2), extended the dataset to include
mouse xenograft tumor samples and used visual inspection
followed by ANOVA and appropriate pair-wise t-test to identify
pre-miRNAs with distinct distributions among the different steps
of endothelial cell transformation. To give a better impression of
within class variability, Figure 3 A–C plots individual dCTU6 for
cellular pre-miRNAs including technical replicates for each class.
The mir-221 pre-miRNA emerged as a biomarker for the
transition from immortalized to tumorigenic endothelial cells
independent of KSHV infection status (Figure 4A). Mir-222 was
co-regulated with mir-221, but did not change as dramatically
(data not shown). Since mir-221/222 exhibit tumor suppressor
activity in endothelial and other cancer models [55,56,65,66], this
suggests that the down-regulation of the mir-221 biomarker is of
biological significance.
The mir-15 pre-miRNA is an example for miRNAs that exhibit
the opposite pattern of transcription as mir-221. Therefore it did
contribute additional information that would have improved
tumor classification. It was high in tumorigenic KSHV-infected
endothelial calls, KS and PEL (data not shown). There was one
significant difference between mir-15 and mir-221 expression: the
KSHV-negative SLK cells transcribed significantly lower levels of
mir-15. In a separate analysis of only the endothelial/KS sample
and excluding SLK cells (data not shown), mir-15 levels correlated
closely with KSHV latent mRNA and miRNA transcription and
can thus be considered KSHV –regulated.
The mir-140 pre-miRNA levels correlated linearly with
tumor status. It was present at appreciable levels only in the
xenograft tumors and KS biopsies, but not KSHV-infected
cells grown in culture (Figure 3B, class ETM, KS). Pre-mir-140
levels did not distinguish tonsil and PEL, since 50% of PEL
lines as well as all KSHV-negative lymphoma lines had only
KS Pre-MicroRNA Profile
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biomarker is limited to the endothelial lineage, but not
lymphatic lineage cancers.
The mir-24-2 pre-miRNA levels were strikingly elevated only in
KS biopsies, not E1 xenograft tumors or PEL (Figure 3C). It
therefore serves as a KS-specific biomarker and not as a marker
for KSHV-associated transformation. This may have utility for
clinical diagnosis, but more importantly it represents at least one
molecular difference between clinical KS lesions and all available
tissue culture models. In other words, any of the KS-specific mir-
24-2 dependent reprogramming of target mRNA and protein
levels is not captured in our current, laboratory-based under-
standing of KS and KSHV biology.
To establish the utility of these four biomarkers for endothelial
cell tumorigenesis, we calculated cumulative density distributions
(cdf) (Figure 3E–G) and a decision tree (Figure 3D). Pre-mir-221
and pre-mir-24-2 showed steep cdfs, which allowed for binary
classification into positive and negative classes. Pre-mir-140
(Figure 3F) showed an almost linear cdf consistent with gradual
changes among multiple sample classes. This is reflected in the
minimal decision tree (Figure 3D) that computes cut-off values for
each miRNA to yield the most parsimonious and accurate
classification schema. Similar decision trees could be derived
using other representative miRNAs from each of the clusters
identified in Figure 2. We also built decision trees based on just
viral pre-miRNA levels (data not shown). These were comparable
Figure 3. Validation of 4 individual biomarkers for endothelial cell transformation. (A–C) Shown are relative transcription levels (dCT) on
the vertical and sample class on the horizontal axis. Dots indicate individual data points (.2 for each sample) for mir-221, mir-140, mir-24-2. (D)
Decision tree of clustering based on just these 3 biomarkers. (E–G) Densityplots of dCT values for these four genes. Relative frequency (in %) is shown
on the vertical axis and relative levels (dCT) on the horizontal axis. The dotted line indicates the cut-off value for class determination.
doi:10.1371/journal.ppat.1000389.g003
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copy number (Figure S3), latent RNA levels and latent pre-
miRNA levels were all correlated (they clustered together by
unsupervised clustering (Figure 1, 2) and increased progressively
with increasing tumorigencity.
In sum, supervised classification established (i) the presence of
molecularly distinct, progressive steps of endothelial cell transfor-
mation and (ii) a set of biomarkers that distinguishes between these
steps.
Discussion
Pre-miRNA profiling
Mature miRNA profiling has previously been used to stratify
lineage types and disease progression stages. Pre-miRNA profiling
has also been used successfully to stratify human tumors
[27,28,29]. We previously profiled pre- and mature miRNAs for
PEL [26] in order to establish a PEL cancer signature, and found
that pre-miRNA profiling offered technical advantages as well as
provided additional, non-redundant information to mature
miRNA-based PEL classification. Here, using 9 primary patient
biopsies and validated pre-clinical cell culture models, we have
ascertained the first pre-miRNA profile of KS.
At the genomic level, we found a variety of changes between
different cell lines and tissue types, but no deletions or
amplifications common to all KS biopsies or all KSHV-positive
samples. At the pre-miRNA level, we identified groups of cellular
miRNAs that define distinctive tissue types. QPCR has been
shown to be an effective form of miRNA profiling. Northern
blotting has limitations including low throughput and poor
sensitivity. Alternative high throughput profiling methods, like
microarrays, require high concentrations of target input, show
poor sensitivity for rare targets, a limited linear range and the need
for post-array validation by real-time QPCR. Therefore, QPCR
appears to be a better method for a limited set of targets such as
the ,650 human miRNAs, and it can be applied easily on a pre-
miRNA level as well.
The miRNA genes are named according to the 60–80 bp
sequence of the pre-miRNA segment [67]. Each miRNA gene
locus produces one pre-miRNA, which in turn can produce one or
two mature miRNAs depending on whether both strands of the
mature product are inserted into the functional RISC complex.
While all miRNA genes, and therefore all pre-miRNAs, are made
of unique sequence, different pre-miRNAs can be processed to
yield an identical mature 22-nucleotide miRNA. For instance,
there are 3 different let-7a genes: let7-a-1, let-7a-2 and let-7a-3,
each located on a different chromosome (9, 13, and 22,
respectively) and subject to different regulatory controls. Pre-
miRNA profiling but not mature miRNA profiling distinguishes
between these transcripts.
How well do pre-miRNA levels correlate with mature miRNA
levels? This seemingly simple question has a non-trivial answer. (i)
We and others have shown that pre-miRNA levels generally
correlate with mature miRNA levels [26,28,29,68,69,70], but we
also found that some pre-miRNAs were present in a slightly
different pattern of expression from the mature miRNAs. The
obvious example, are the aforementioned pre-miRNA paralogs,
which encode the same mature miRNA, but reside on different
genomic locations. Furthermore, there are well-documented
instances, where SNPs affect Dicer processing [71,72]. These
exceptions are informative in their own right and only simulta-
neous quantification of pre- and mature miRNA levels can identify
these. In the present case mature mir-221 levels were also
downregulated in KS and PEL compared to non-tumorigenic
controls, but for the two others (mir-140, mir-24-2) we could not
establish a statistically significant pattern based on mature miRNA
levels (O’Hara et al., in press). (ii) The two assays (mature miRNA
and pre-miRNA) measure two different events and thus provide
non-redundant information. The pre-miRNA pool represents an
intermediate step and thus responds without delay to changes in
cellular transcription. Pre-miRNAs are co-transcriptionally pro-
cessed [73,74]. They have a short half-life, much like mRNAs, and
thus provide a sensitive read-out for the purpose of tumor
profiling. By contrast, mature miRNAs are part of the relatively
stable RISC complex and thus provide a time-delayed read-out of
the state of the cell. (iii) The two assays (mature miRNA and pre-
miRNA) have different performance characteristics. Unfortunate-
ly, these are different for each miRNA (data not shown). Even if
relative levels of pre- and mature miRNAs correlate, the different
assay formats for pre- and mature miRNAs have different
sensitivities, different response characteristics and a different lower
limit of detection (much of which is dependent on the miRNA-
specific primer sequences) and thus they have a varying ability to
distinguish between the presence and absence of a miRNA
sequence.
Pre-miRNA profiling defines progressive stages of
endothelial cell transformation
In the case of KS and its related cell culture and animal models,
each class in our collection (E, EK, ET, ETM, KS, PEL) exhibited
a distinctive cellular miRNA profile (Figure 4). Even though we
found some differences in the transcription pattern between
individual KSHV miRNAs (unpublished), the KSHV miRNA
levels as a group correlated with an increasing tumor-forming
capability of infected cells (p#10
210 by ANOVA of linear model).
They were present in KSHV-infected HUVEC clones, high in
E1/L1 cells in culture, higher in E1 mouse tumors and KS lesions
and highest in PEL. Of note, the non-tumorigenic EC clones were
made with JSC-1 derived KSHV [75], whereas TIVE E1/L1
clones were made from BCBL-1 derived KSHV [40], which may
yield to a difference in miRNA regulation. KSHV gene copy
number also increased with increasing tumorforming ability in this
set of samples. At present we cannot discern whether high KSHV
pre-miRNA levels are a driver for or a consequence of increased
Figure 4. Model of KSHV-dependent progressive transforma-
tion of endothelial cells as identified by pre-miRNA clustering.
Upon KSHV infection, KSHV miRNAs and cellular miRNAs are induced.
Through various stages of transformation, additional cellular miRNAs
are induced and KSHV miRNA expression increases. E indicates primary
endothelial cells. EK indicates endothelial cells, which can grow in
reduced serum due to KSHV infection. ET indicates KSHV infected
endothelial cells, which can form tumors in nude mice, such as E1 and
L1 TIVE cells. KS indicates Kaposi sarcoma, which is the only cell type to
experience notable levels of lytic reactivation with KSHV infection.
doi:10.1371/journal.ppat.1000389.g004
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other KSHV isolates that may contribute to variability among the
individual samples [76]. Sequence variation is more pronounced
for pre-miRNAs because of length (70 vs 22 nt) and less selective
pressure for non-essential positions.
Our data support a stepwise progression towards KS based on
cellular pre-miRNA patterns alone (Figure 3D) or after integration
of the KSHV miRNA data (Figure 2). This model is exemplified in
Figure 4. Initially, normal endothelial cells (E) are infected with
KSHV to yield stage EK. Both the uninfected and infected
endothelial cells share a common endothelial lineage pre-miRNA
signature (Figure 4, group I). In addition, all KSHV-infected cells
express low levels of KSHV miRNAs as well as a distinct group of
cellular miRNAs (Figure 4, group IV). These are able to grow in
reduced serum, indicating that KSHV is a transforming virus.
However, these cell lines do not form tumors in mice and are
therefore not oncogenic. The viral life cycle in these cells remains
tightly latent. The E1 and L1 TIVE cells are infected cells that
have undergone a second transformation event. As a result cells
progress to the ET stage. These cells are capable of forming
tumors in mice and express intermediate levels of KSHV miRNAs
and a distinctive group of pre-miRNAs (Figure 4, group II). While
these cells are highly transformed, similar to KS, the life cycle of
the virus is still tightly latent. We were able, for the first time, to
also profile primary KS biopsies. KS lesions exhibited the highest
levels of KSHV miRNAs, as compared to other infected
endothelial cell samples. PEL exhibited still higher levels due to
a higher genome copy number. In addition, unsupervised
clustering identified a group of pre-miRNAs that are highly
upregulated only in primary KS lesions (Figure 4, group III).
Unlike cell culture models, which are tightly latent, KS lesions are
known to undergo spontaneous lytic reactivation to varying
degrees [77]. In sum, each sample class profiled had a unique
set of highly transcribed cellular pre-miRNAs, independent of the
presence of virus, and a second set of pre-miRNAs that were
dependent on the presence of KSHV.
There exists an important distinction between tumorigenicity
with is a phenotype of cell culture models and tumor take, which is
a phenotype of primary tumor explants. In experimental
transformation models such as NIH3T3 cells tumorgenicity in
immune deficient mice is conferred by the adding one or two
single oncogenes. In tumor explant models tumor take is defined as
how many mice will form transplantable tumors after injection of a
given dose of primary tumor cells. Tumor take is highly variable
among cancer types and even individuals. It does necessarily
correlate with clinical aggressiveness and does not easily correlate
with a single gene. KS and EBV+ nasopharyngeal carcinoma are
examples of highly aggressive, angiogenic tumors, which almost
never yield stable cell lines in culture or transplantable xenografts
in nude mice.
Individual miRNAs emerge as novel tumor-stage specific
biomarkers with important biological functions
Mir-221 is a tumor suppressor for endothelial cell lineage
cancers independent of KSHV infection. We found the highest
levels of pre-mir-221 in uninfected and KSHV latently infected
tert-HUVEC and tert-HMVEC cell lines. This corroborates prior
reports of high mir-221 levels in endothelial cell lines [66,78,79].
High levels of mir-221 exert anti-angiogenic effects in HUVEC
cells, resulting in inhibited tube formation, migration and wound
healing [66]. This anti-angiogenic effect correlated with downreg-
ulated expression of the mir-221 target protein c-kit [66]. In Dicer
siRNA-transfected cells, mir-221 expression has also been shown
to indirectly downregulate expression of endothelial nitric oxide
synthase (eNOS) [78]. Nitric oxide is a key regulator of endothelial
cell growth, migration, vascular remodeling and angiogenesis. The
picture is more complicated, though, since depletion of mir-221 in
HUVEC cells causes secondary changes in other miRNAs [66,80];
these included many that are predicted to also target c-kit. C-kit
expression was also reduced by mir-221 in hematopoietic
progenitor cells. In this system, mir-221 also inhibited proliferation
[81]. Additional targets for mir-221 include CDKN1B/p27 and
CDKN1C/p57, which are cell cycle regulators [56,59,65,82].
Disregulation of mir-221 has been found in melanomas due to
silencing of the promyelocytic leukemia zinc finger (PLZF)
transcription factor [83]. In summary, mir-221 seems to possess
endothelial cell lineage-specific differentiation functions as well as
general tumor/proliferation suppressor functions.
Pre-mir-34a and c were found at detectable levels in endothelial
cells, PEL and KS, as these tumors retain wild-type p53 (Figure 1).
The miR-34 promoter is p53-responsive [61,64,84,85,86,87]. Of
all three p53-responsive miRNAs, mir-34a appears to be the most
responsive in terms of fold change [61]. High levels of miR-34 are
consistent with the biology of PEL and KS, which are unusual
among human cancers because they almost universally retain fully
functional, wild type p53 [88,89]. Three different miR-34 genes
are present in the human genome. Mir-34a is located within the
second exon of a non-coding gene, which contains a predicted
p53-binding site. Genes mir-34b and mir-34c are located within a
single non-coding precursor with a transcriptional start site
adjacent to a predicted p53-binding site [86]. All three genes
produce mature miRNAs with an identical seed sequence. It will
be interesting to determine whether mir-34a, similar to p53-
responsive mRNAs [88], can be even further induced upon
chemotherapy in PEL and KS.
Pre-mir-140 levels were tightly correlated with KSHV latent
mRNA (LANA) and latent miRNA levels in KS and KS tumor
models. Currently, little is known regarding mir-140 expression
profiles or possible mRNA targets [90]. TargetScan miRNA target
software indicates a number of possible targets for mir-140,
including E2F3, a member of the E2F family of transcription
factors essential for cell cycle regulation. This prediction, however,
awaits experimental verification.
Pre-mir-24 emerged as a highly specific KS biomarker compared
to all other pre-miRNAs in our array. Mir-24 has been shown to be
important in cell-cycle regulation, cell growth and differentiation in
a variety of cell types [91,92]. However, these as well as functional
studies on mir-24 and its targets are still in the early stages.
Tantalizing data predict p16 and dehydrofolate reductase (DHFR)
as mir-24 targets among others [93,94,95,96,97].
In summary, the first pre-miRNA profiling of primary KS
tumor biopsies and the subsequent comparison to well-studied
culture and mouse xenograft models of KS yielded a progression
model for endothelial lineage cancer and KS (Figure 4) akin to the
now classical model for colorectal cancer progression [98]. We
hope that this will benefit basic and translational studies of KS,
which remains the most frequent cancer in people living with
HIV/AIDS today. We also identified specific KSHV and KS-
associated pre-miRNAs, foremost among them mir-221, mir-140,
mir-15a and mir-24. Based upon their strength of association with
specific stages of endothelial cell tumor progression, we speculate
that these are also functionally involved in KS tumorigenesis.
Materials and Methods
Cell culture and clinical biopsies
Cells were grown in continuous culture on a 3T3-like schedule,
i.e. passaged at subconfluency, and RNA collected in log phase,
KS Pre-MicroRNA Profile
PLoS Pathogens | www.plospathogens.org 9 April 2009 | Volume 5 | Issue 4 | e1000389typically 24–48 hrs after reseeding. All B and T cells were cultured
in RPMI containing 25mM HEPES, 10% fetal bovine serum
(AP2, AP3, AP5 in 20%), 0.05 mM 2-mercaptoethanol, 1 mM
sodium pyruvate, 2 mM L-glutamine, 0.05 ug penicillin/mL, and
20 U streptomycin/mL at 37u and in 5% CO2. TIVE cells were
cultured in DMEM containing 10% fetal bovine serum, 2 mM L-
glutamine, 0.05 ug penicillin/mL, and 20 U streptomycin/mL at
37u and in 5% CO2. HUVEC-hTERT cells were cultured in
EGM-2 containing 10% fetal bovine serum, hydrocortisone,
hRGF, VEGF, R3-IGF, Ascorbic acid, hEGF, GA-1000 and
heparin at 37u and in 5% CO2. HUVEC+KSHV cells were
cultured in the same media also containing 0.5pM/ul puromycin
to maintain selection. De-identified frozen tonsil and melanoma
tissue biopsies were obtained from the cooperative human tissue
network (CHTN). KS frozen tissue biopsies were obtained after
informed consent at University of Miami, Prof. Edgard Santos
University Hospital, Salvador, Brazil and Beth Israel Deaconess
Medical Center. All cell lines and references are described in
Table S1.
DNA and RNA isolation
DNA was isolated from cell lines and samples using the Wizard
SV Genomic kit (Promega, Madison, WI). Total RNA was isolated
using Triazol (Sigma-Aldrich, St Louis, MO) as previously
described [78]. Total RNA was quantitated on a Nanodrop and
equal amounts of RNA were subjected to DNase I treatment
(Ambion, Austin, TX). RNA was reversed transcribed using the
cDNA Archive Kit (Applied Biosystems, Foster City, CA), with the
addition of RNase Inhibitor and, in pre-miRNA screening, the
additions of T4 gene protein 32. RNA integrity was evaluated
using a 2100 Bioanalyzer Series C (Agilent, Santa Clara, CA).
Total RNA was measured using the RNA 6000 Series II Nano kit
and small RNA was measured using the Small RNA kit, according
to the manufacturers recommendations. All Chips were analyzed
using 2100 Expert software version B.02.04. The average RNA
integrity value for total RNA among all samples profiled was
8.0062.60.
Real-time QPCR
For DNA and pre-miRNA expression profiling, two 96-well
plates containing 372 different primers were used. These primers
represent 168 cellular and 12 viral pre-miRNA targets, as well as 6
cellular and viral control miRNA targets. All primers conform to
universal real-time PCR conditions with a predicted Tm of 60 and
100-bp or smaller amplicon length. Real-Time QPCR was
conducted under universal cycling conditions of 40 cycles with
SYBR Green as the method of detection following our previously
validated methods. A 36ul reaction mix was made using a CAS-
1200 robot that uses filtered carbon-graphite pipette tips (Tecan
Inc., Durham, NC) for liquid level sensing, allowing for a pipetting
accuracy of 0.1ul. The reaction mix was then distributed in
triplicate into a 384-well plate using a Matrix repeat pipettor
(Thermo Inc.). The final primer concentration was 250nM in total
of the 9ul reaction volume. Because pre-miRNA-specific primers
also detect the corresponding gene, these primers were used for
DNA gene profiling as well. For DNA QPCR, each reaction
contained 1.67ng DNA/ul. For pre-miRNA QPCR, 40ul of the
100ul RT reaction was used for each 384 well plate, yielding a
final amount of 0.1ul cDNA per each 9ul reaction. Real-time
QPCR primers against 93 mature miRNAs and 1 cellular mRNA
were used according to the manufacturers protocol (Applied
Biosystems Inc.). The combined pipetting and instrument error for
all of the QPCR reactions was less than 6% (data not shown). All
reactions were done in technical triplicates. QPCR was performed
on a 384 well LC480 (Roche Inc.) platform.
Statistical analysis
Data were collected in triplicate for each RT reaction. Since
averaging these replicates would mask individual reaction failures,
we clustered all replicates individually after masking outliers. Each
array of 160 primers contained four separate reactions for U6
yielding six CTU6. We calculated the mean and median of these
four reactions to yield ^CTU6. The maximal difference between
mean and median was 0.30 CT units. All other CT data were
normalized to ^CTU6. This yielded dCT for each primer/sample
combination. The dCT were normalized to median for each array
and subjected to unsupervised clustering using a Correlation
metric [51] and the program Arrayminer
TM.
Our exploratory cluster analysis included all primers and all
samples. However, for statistical analysis we excluded primers,
which yielded CT ,38 for the non-template and reverse
transcriptase negative controls. We also excluded primers, which
did not yield a signal (CT,38) in at least one of the samples as
uninformative. We used QQ plots for each sample and
Kolgomoroff-Smirnoff statistics to test for normal distribution
across arrays (data not shown).
For miRNA gene copy number analysis, data were collected in
triplicate (or duplicate) for each sample. Since averaging these
replicates would mask individual reaction failures, we clustered all
replicates individually after masking outliers. Each set of 160
primer pairs contained four separate reactions for U6 yielding four
CTU6. We calculated the mean of these four reactions to yield
^CTU6. In only two samples did the median deviate significantly
from the mean based on an analysis of residuals (data not shown).
This suggested individual reaction or pipetting failures. We
imputed modified ^CTU6 for those singular cases based on the
following rule: if ,50% of replicates differed by .1 CT from the
mean of the remainder, they were replaced by the mean of the
remaining data points. After imputation, the mean ^CTU6 across
all samples and all technical replicates (n=348) was 20.9461.97
with a median of 21.26. For individual quadruplicate CTU6
measurements, the SDs ranged from 0.03 to 1.00 CT. 71.26% of
SDs for technical replicates were #0.32 CTs. Hence, this array
identified 2-fold changes in copy number. All other CT data were
normalized to ^CTU6. This yielded dCT for each primer/sample
combination. The dCT were subjected to unsupervised clustering
using an Euklidian metric and visualized on a log2 scale [51].
For supervised comparisons between two classes, we used the
Welch-modified t-test as implemented in the R statistics program
[99]. This yielded unadjusted, univariate p values for each
individual miRNA gene. This particular variant of the t-test
allows for unequal variances between the two classes. An analysis
of variances showed that most miRNA genes had identical
variances between the KSHV-infected (n=53) and normal tissue
(n=18) data sets. We used q-value computation [100], to assess
the false discovery rate. The statistical methods for supervised
comparisons between two classes of pre-miRNAs were as
described above for miRNA gene loci. We only report the
minimal set of miRNA genes for which we do not expect any false
positives. The Bonferroni-adjusted p-value was #0.05 for each of
the hits. Decision trees were computed as implemented in R [99]
using 10 fold cross-validation.
Quality control
To monitor RNA integrity and yield, we used the Agilent
bioanalyzer (Figure 5A–D). The Agilent bioanalyzer provides two
chips with different size resolution. The small RNA chip resolves
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RNA species from 25–6000 nt (Figure 5A,B). It allows size
determination as well as quantitation. We compared two RNA
preparations: total RNA isolated with Triazol and total RNA
isolated with Triazol followed by high molecular weight depletion
(HMWD). The total RNA isolation with Triazol
TM retained the
highest concentration of miRNAs (20.5 pg/ml) while preserving
overall RNA integrity as measured by RIN value (9.7), which is a
proprietary estimate based on ratio of 28S to 18S peak (Figure 5A).
Subsequent HMWD as required for other mature miRNA
profiling approaches (e.g. [101]) depleted mRNA and rRNA, as
expected. It did not change the relative abundance of miRNA
(,22nt) to pre-miRNA ,70 nt), but decreased overall small RNA
yield by half (10.5 pg/ml). Hence, we used total RNA for all
further studies.
We used real-time QPCR to determine individual pre-miRNA
levels as per our published procedures [26]. Individual miRNA
CT readings were normalized to CT of U6 rRNA (dCTU6)t o
account for variation in sample input RNA or DNA. However, we
generally obtained more consistent results if we used very similar
amounts of RNA (as determined by nanodrop
TM based quanti-
tation) for the reverse transcriptase (RT) reaction. The reason for
this pre-RT normalization step is that the RT reaction, too, has a
linear range just as the real-time QPCR reaction, otherwise the
RT reaction may be saturated or, in case of diluted samples, of
lower than expected RT efficiency. Figure 5E shows average raw
CT values for U6 for each DNA sample, aggregated by sample
class. Figure 3F shows average CT values for U6 for each post RT
cDNA sample, aggregated by sample class. Again, variation is
minimal except for two outliers (HMVEC and KS 101), for which
we had only small amounts of RNA available. Though even those
two samples had U6 CT values of #27 cycles. Since we ran a 40
cycle QPCR reaction, this gave us an assay range of 2
(27-40=13)=0
to 8192 fold above the level of detection.
All experimental samples were run in triplicate for RT-positive
and DNA reactions. Pooled samples were run in triplicate for RT-
negative control reactions. Non-template control (NTC) reactions
were run to assure that the primers were free of contamination and
did not yield non-specific products or primer dimers at a
significant rate. A reaction was considered positive if the
corresponding CT was greater than 38.00 cycles. To remove
primers with substantial capacity for primer dimer formation, any
primer pair with mean CT ,38.00 in the RT- or NTC reactions
was omitted from further analysis. This removed 8 cellular pre-
miRNA and 1 viral miRNA primer pairs (KSHV-mir-k12-10a)
from our original set [26]. Conversely, any primer pair that failed
to efficiently amplify the corresponding DNA target (mean CTDNA
.38.00) was also omitted from further analysis. This filtering
removed 15 cellular pre-miRNA primer pairs, 1 viral miRNA
primer (KSHV-mir-k12-3). It also removed all no primer controls
from the data set. In all, the final array included 160 primer pairs,
representing 145 cellular miRNAs, 6 KSHV miRNAs, 3 EBV
miRNAs, 2 KSHV mRNAs and 4 cellular rRNAs (U6). These
were run in parallel for each sample. The distribution of all data
used in the analysis was as follows: for the NTC (Figure 5J), 203 of
5120 reactions (3.96%) of the reactions had a CT,38. These were
randomly distributed across all samples and all primers. For the
RT- reactions (Figure 5G), 286 of 5920 (4.83%) of the reactions
Figure 5. QPCR quality control. Agilent Bioanalyzer
TM RNA chip
results are shown for two common extraction methods of RNA. The BC2
cell line was used. (A) The RNA nanochip on Triazol
TM extracted total
RNA has a calculated concentration of 237.5 ng/ul, using peak
comparison, and a RNA integrity value of 9.7, while (B) the high
molecular weight deleted sample (HMWD) is depleted for the rRNA and
tRNA necessary for these calculations. (C) The small RNA chip on the
total RNA sample has a concentration of 20.5 pg/ml as measured by
area between 20–40 nucleotide while (D) the HMWD depleted sample
has only 10.5 pg/ml in the same region. Average U6 values of all
samples for the DNA (E) and RNA (F) are shown in box and whisker
plots. C indicates endothelial cell culture models, both infected and
uninfected, KS indicates primary KS biopsies, L indicates B and T cell
lymphoma cell lines, P indicates PEL, and T indicates Tonsil Tissue.
Outliers are shown in open dots. Histograms of individual QPCR
reactions are shown for all reaction types, with frequency shown on the
y-axis and CT value shown on the x-axis. A CT value #38.00 is
considered positive. (G) For all RT negative reactions (n=5,920), 4.83%
are positive. (H) For all RT positive reactions (n=20,000), 41.50% are
positive. (I) For all DNA (n=13,920), reactions 90.28% are positive. (J) For
all non-template water control reactions (n=5,120), 3.96% are positive.
doi:10.1371/journal.ppat.1000389.g005
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indicated perfect overlap between the positive samples indicating
these were incidences of shared positivity and should therefore
only be counted once (data not shown). Therefore the false positive
rate was 4.83%. In the DNA samples (Figure 5I), 12,567 of 13,920
(90.28%) of the reactions had CT,38. Given that less than 5% of
the total number of reactions represent viral targets, the presence
of which is variable from sample to sample, the remaining negative
values most likely indicate deletions of miRNAs in certain samples.
The distribution was unimodal and followed a normal distribution
(data not shown). Finally, the RT-positive (Figure 5H) set
contained 8,299 of 20,000 (41.50%) positive reactions (CT ,38)
in total. These are less than half the positive reactions recorded for
the corresponding DNA results. This means that although we
could detect 86% of all miRNA genes (DNA) in all samples, only
45.54% were actively transcribed in our set of samples. This
means that half of all miRNAs in our array were transcribed in the
endothelial cell lineage. This is consistent with the known tissue
specificity of miRNAs and underscores their value as differentially
expressed biomarkers. This is likely due to a combination of
factors, including tissue type and developmental stage. For
instance, we would not expect liver or brain-specific miRNAs to
be present in any of our samples.
Supporting Information
Figure S1 Minimal influence of proliferation phase on pre-
miRNA levels in E1 and L1 cells. (A) Clustering analysis indicates
few miRNAs changed in expression pattern during growth phases.
(B) Principal component analysis of clustering indicates non-
overlapping clusters.
Found at: doi:10.1371/journal.ppat.1000389.s001 (1.57 MB TIF)
Figure S2 Pair-wise comparisons of dCT values for pre-
miRNAs. (A) HUVEC against HMVEC, (B) KSHV-infected
HUVEC against EC, (C) E1/L1 against KSHV-infected HU-
VEC, (D) E1/L1 cells in culture against E1 tumors, (E) KS
biopsies against E1 tumors, (F) KS tumors against E1/L1 cell lines.
Plotted are median dCTU6 values.
Found at: doi:10.1371/journal.ppat.1000389.s002 (2.66 MB TIF)
Figure S3 Relative KSHV genome copy number (2
dCTU6) based
on real-time QPCR for the LANA orf. The classes are (E)
uninfected endothelial cells, (EK) KSHV infected endothelial cells,
(ET) KSHV-infected endothelial cells, which can form tumors in
nude mice (E1 and L1 TIVE), (P) Pel lines, (TN) tonsil. Shown also
is the fold difference in relative copy number between KSHV-
positive classes. Neither E nor RN yielded a detecable signal (1
copy per ,100,000 cell equivalents).
Found at: doi:10.1371/journal.ppat.1000389.s003 (2.26 MB TIF)
Figure S4 Pre-miRNA profiling throughout the cell cycle
indicates few miRNAs are changed. (A) Growth curves for the
E1 (red dots) and L1 (blue triangles) cell lines. Number of cells per
T75 flask is shown on vertical axis and time in hours since seeding
on the horizontal axis. Logarithmic indicates the time points that
were averaged to yield logarithmic phase pre-miRNA levels and
Stationary indicates time points that were averaged to yield
stationary phase pre-miRNA levels. (B–E) Pair-wise comparisons
of average log-pre-miRNA levels (dCTU6) of proliferation phases
and cell lines. (Only data points with SD #3 were included in the
comparison).
Found at: doi:10.1371/journal.ppat.1000389.s004 (1.94 MB TIF)
Table S1 Indicated are the samples profiled, viral status and
original cell line reference paper or sample source.
Found at: doi:10.1371/journal.ppat.1000389.s005 (0.08 MB
DOC)
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